news
Formulation development outsourcing market to be worth over $60bn by 2030
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
List view / Grid view
Contract Research Organisations (CROs)
news
WuXi Biologics awarded for excellence
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and Safety accolade for the second time at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics-300x278.jpg)
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics.jpg)
news
WuXi announces record figures after successful year
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
news
Global LIMS market to grow to $3.56bn by 2030
Research suggests rising demand for lab automation will help promote the growth of the laboratory information management system (LIMS) market.
article
Putting safety at the heart of clinical research outsourcing strategy
Pharma companies outsourcing clinical research support without focusing on safety are paying the price. Here, Natalia Vlcek, Pharmacovigilance Manager and EU QPPV at Arriello Group, offers some practical tips for ensuring best practice when it comes to safety in clinical research outsourcing.
news
Calvert Laboratories acquired by Altasciences
According to Altasciences, the completed acquisition will increase small molecule expertise and add various study capabilities to its current pre-clinical offering.
news
Charles River Laboratories generates $824 million in first quarter
Charles River Laboratories International’s first quarter revenue was approximately 17 percent higher in Q1 2021, with organic revenue growth of 13 percent.
news
Global pharmacovigilance market to value almost $15bn by 2028
Research suggests outsourcing and the increasing incidence of adverse drug reactions (ADR) will be primary drivers of growth in the global pharmacovigilance market.
![Thermo Fisher Scientific company office with large company logo in Silicon Valley, US [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Thermo-Fisher-Scientific-300x278.jpg)
![Thermo Fisher Scientific company office with large company logo in Silicon Valley, US [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Thermo-Fisher-Scientific-e1618570463300.jpg)
news
Thermo Fisher to acquire PPD for over $17 billion
The acquisition, anticipated to complete in 2021, allows Thermo to expand its ‘one-stop-shop’ of services into running clinical trials.
news
Biotech and pharma services outsourcing market to be worth over $91bn by 2028
A new report suggests the global biotechnology and pharmaceutical services outsourcing market will grow because of the pandemic and rising drug development costs and R&D investments.
webinar
Comparing EMA and Health Canada CTA submission for Phase I trials to US FDA IND application
13 January 2021 | By Altasciences
Watch this webinar on-demand which presents an overview of a foreign health authority’s requirements for gaining approval to conduct an FIH clinical trial by comparing Health Canada and European Medicines Agency (EMA) Clinical Trial Authorisation (CTA) processes to that of the FDA IND submission.
article
New opportunities for the global API market
Active pharmaceutical ingredients (APIs) are primary components in the manufacture of drugs, yet this global market experiences numerous challenges. Regulatory pressure, pricing arbitrages, a shift to digital manufacturing and patents for blockbuster drugs are chief among them, but the COVID-19 pandemic added a further hurdle as governments globally decided to…
article
Clinical trial disruptions: is it all down to COVID-19?
This article explores how COVID-19 has impacted clinical investigation sites and what companies could do to mitigate the effect on trials moving forwards.
article
Maintaining pharmaceutical operations during a pandemic through innovation and remote technologies
G Balaji and Ravi Kalla explains how Pharma 4.0 can be implemented at a CRO to enable work to continue even during a global pandemic.
news
Top six CROs on Japanese market revealed in new report
Researchers have revealed the top six CROs that dominate the Japanese market and are expected to continue in their position.
